About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Biocon Ltd.
Change Company
BSE Code
532523
ISIN Demat
INE376G01013
Book Value
166.61
NSE Code
BIOCON
Dividend Yield %
0.13
Market Cap
615458.68
P/E
8317.01
EPS
0.05
Face Value
5
1 Week
1 Month
3 Months
6 Months
1 Year
13-Mar-2026
Biocon’s arm gets USFDA’s nod for ANDA of Liraglu...
05-Mar-2026
Biocon informs about analyst meet
25-Feb-2026
Biocon gets USFDA’s nod for Liraglutide Injection
25-Feb-2026
Biocon inches up on getting USFDA’s nod for Lirag...
25-Feb-2026
Biocon informs about investor presentation
17-Feb-2026
Biocon informs about investors meet
13-Feb-2026
Biocon reports over five-fold jump in Q3 consolid...
13-Feb-2026
Biocon informs about presentation
13-Feb-2026
Biocon moves up on reporting over five-fold jump ...
29-Jan-2026
Biocon gets VAI status for Andhra Pradesh’s API f...
29-Jan-2026
Biocon declines on getting VAI status for Andhra ...
28-Jan-2026
Intimation Of Record Date For Buy Back Of Listed...
28-Jan-2026
Biocon informs about press release
22-Jan-2026
Biocon hikes stake in Biocon Biologics to 98%
20-Jan-2026
Biocon informs about disclosure
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.